摘要
目的比较乳果糖联合利福昔明与单用乳果糖治疗肝性脑病(hepatic encephalopathy,HE)的疗效。方法全面检索Cochrane Library、Pub Med、Web of Science、Embase、中国生物医学文献数据库、中国知网、维普及万方数据库中关于比较乳果糖联合利福昔明与单用乳果糖治疗HE患者的随机对照试验(randomized controlled trials,RCTs),检索时间为从建库至2019年3月17日。应用Stata12.0软件进行Meta分析。主要结局指标为治疗的有效率及病死率。结果本研究共纳入5篇RCTs,包括563例患者。Meta分析表明,乳果糖联合利福昔明较单用乳果糖治疗HE患者的有效率更高(RR=1.261,95%CI:1.122~1.417,P <0.001);但病死率差异无统计学意义(RR=0.656,95%CI:0.376~1.145,P=0.138)。结论与单用乳果糖相比,联合利福昔明的组合方案治疗HE患者的疗效更佳,但不能降低病死率。
Objective To comprehensively compare the efficacy of lactulose combined with rifaximin and lactose alone for patients with hepatic encephalopathy(HE). Methods The Cochrane Library, PubMed, Web of Science, EMBASE, CBM, CNKI, VIP and Wan Fang digital database were searched, only randomized controlled trials(RCTs) of the treatment of HE with lactulose plus rifaximin and lactulose alone were included. The retrieval time was established for the database until March 17, 2019. Meta-analysis was performed by Stata 12.0 software. The primary outcome indexes were efficacy and mortality. Results Overall, five RCT studies comprising 563 patients were included. Lactulose combined rifaximin was more effective than lactulose alone in the treatment of patients with HE(RR = 1.261, 95%CI: 1.122~1.41, P < 0.001). However, the difference of the mortality was not significant(RR = 0.656, 95%CI: 0.376~1.145, P = 0.138). Conclusion Lactulose combined with rifaximin is more effective than lactulose alone in treatment of patients with HE, but which can not reduce the mortality.
作者
贺秋凤
胡蓉
曾义岚
康信通
陈治莉
杨启
邓杨
张琼
毛创杰
李萍
HE Qiu-feng;HU Rong;ZENG Yi-lan;KANG Xin-tong;CHEN Zhi-li;YANG qi;DENG Yang;ZHANG Qiong;MAO Chuang-jie;LI Ping(Department of Hepatology,Chengdu Public Health Clinical Medical Center,Chengdu,610066,China)
出处
《中国肝脏病杂志（电子版）》
CAS
2019年第4期32-36,共5页
Chinese Journal of Liver Diseases：Electronic Version
基金
四川省科技计划课题（2017TJPT0013）
关键词
肝性脑病
利福昔明
乳果糖
疗效
荟萃分析
Hepatic encephalopathy
Lactulose
Rifaximin
Efficacy
Meta-analysis
